本文選題：黑素瘤　切入點(diǎn)：A細(xì)胞　出處：《中國(guó)腫瘤生物治療雜志》2015年04期

【摘要】：目的:探索4EGI-1對(duì)黑素瘤A375細(xì)胞中AKT通路的激活作用及后者對(duì)4EGI-1抑制A375細(xì)胞增殖的影響。方法:用20、40、60μmol/L的4EGI-1處理黑素瘤A375細(xì)胞12、24 h,Western boltting檢測(cè)4EGI-1對(duì)A375細(xì)胞中AKT磷酸化的影響;A375細(xì)胞分別受4EGI-1(40μmol/L)、BEZ235(5μmol/L)、4EGI-1(40μmol/L)+BEZ235(5μmol/L)聯(lián)合處理,CCK-8實(shí)驗(yàn)和流式細(xì)胞術(shù)分別檢測(cè)4EGI-1、BEZ235單獨(dú)或聯(lián)合處理對(duì)A375細(xì)胞增殖和細(xì)胞周期的影響,Western boltting檢測(cè)對(duì)細(xì)胞周期相關(guān)蛋白Cyclin D1表達(dá)的影響。結(jié)果:4EGI-1促進(jìn)A375細(xì)胞中AKT的磷酸化,且具有劑量依賴性;而BEZ235能夠拮抗4EGI-1對(duì)AKT的促磷酸化作用。與4EGI-1組和BEZ235組相比,聯(lián)合組的A375細(xì)胞增殖抑制率顯著升高[24 h時(shí),4EGI-1組和BEZ235組抑制率分別為(7.6±1.2)%和(2.4±3.1)%,而聯(lián)合組抑制率為(19.8±4.3)%;P0.05],S期細(xì)胞比例顯著降低(4EGI-1組和BEZ235組S期細(xì)胞比例分別為25.65%和25.82%,聯(lián)合處理組細(xì)胞S期為13.08%;P0.05),Cyclin D1表達(dá)顯著降低(4EGI-1組和BEZ235組Cyclin D1相對(duì)表達(dá)值為0.81±0.04和0.76±0.04,聯(lián)合處理組細(xì)胞Cyclin D1相對(duì)表達(dá)值為0.25±0.03;P0.05)。結(jié)論:AKT反饋激活拮抗4EGI-1對(duì)黑素瘤A375細(xì)胞的抑制作用,聯(lián)合使用AKT抑制藥物能夠增強(qiáng)4EGI-1對(duì)A375細(xì)胞的生長(zhǎng)抑制作用。
[Abstract]:Aim: to investigate the effect of 4EGI-1 on the activation of AKT pathway in A375 cells and the effect of 4EGI-1 on the proliferation of A375 cells.Effects of proliferation and cell cycle on the expression of cell cycle associated protein Cyclin D1 by Western boltting.Results: the AKT phosphorylation of A375 cells was enhanced by 1: 4EGI-1 in a dose-dependent manner, while BEZ235 antagonized the phosphorylation of AKT by 4EGI-1.Compared with the 4EGI-1 group and the BEZ235 group,The expression of Cyclin D1 in the S phase of the treated group was 13.08. The relative expression of Cyclin D1 in the EGI-1 group and the BEZ235 group was 0.81 鹵0.04 and 0.76 鹵0.04, and the relative expression value of Cyclin D1 in the combined treatment group was 0.25 鹵0.03p0.05.Conclusion the feedback activation of 4EGI-1 antagonizes the inhibitory effect of 4EGI-1 on A375 cells, and the combination of AKT inhibitor can enhance the growth inhibition of A375 cells induced by 4EGI-1.
【作者單位】： 貴陽(yáng)醫(yī)學(xué)院附屬醫(yī)院皮膚科;
【基金】：貴州省中藥現(xiàn)代化專項(xiàng)項(xiàng)目資助(No.20125018)~~
【分類號(hào)】：R739.5

【共引文獻(xiàn)】

相關(guān)期刊論文 前8條

1 趙興旺;吳冰;焦慎超;李晶晶;樊印波;劉麗娜;趙睿;李青青;劉丹;趙臨襄;;真核細(xì)胞翻譯起始因子4E相關(guān)通路小分子抑制劑的研究進(jìn)展[J];國(guó)際藥學(xué)研究雜志;2013年04期

2 陽(yáng)諾;馬輝;冼磊;陳銘伍;郭建極;胡松;;NSCLC組織中nm-23和VEGF蛋白的表達(dá)及其臨床意義[J];海南醫(yī)學(xué);2014年07期

3 謝金龍;羅招陽(yáng);袁恩健;陳永春;左建宏;;Bcl-2與Ki-67蛋白在喉鱗癌中的表達(dá)檢測(cè)及臨床相關(guān)性分析[J];中南醫(yī)學(xué)科學(xué)雜志;2014年06期

4 石芳;徐戰(zhàn)戰(zhàn);左澤華;趙e，

本文編號(hào)：1726462